<DOC>
	<DOCNO>NCT01224717</DOCNO>
	<brief_summary>This study design provide information bone-anabolic response PTH134 administer orally , comparison ForsteoÂ® , sub-cutaneous form teriparatide , active ingredient PTH134 .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Oral Doses PTH134 Post-menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal woman osteoporotic/osteopenic additional risk factor 45 80 year old Use estrogen hormone replacement therapy Use parathormone parathormone fragment , calcitonin , aluminum supplement , within 12 month prior first dose . Use bisphosphonates strontium ranelate Cancer history malignancy organ system Any radiation therapy skeleton . Any know clinically significant disease affect calcium metabolism . Any history metabolic disorder include Paget 's disease , osteogenesis imperfecta , osteomalacia . History clinical evidence impairment thyroid function Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Osteoporosis</keyword>
</DOC>